Industry update covering August 2018

[1] [Anonymous], FDA APPR GAL MIG TRE

[2] [Anonymous], 2018, M HIGHL COMM MED PRO

[3] Boehringer Ingelheim the UK Cystic Fibrosis Gene Therapy Consortium, IMP INN OXF BIOMEDIC

[4] FDA, FDA APPR NEW TREATM

[5] Type I interferon blockade in systemic lupus erythematosus: where do we stand? [J]. RHEUMATOLOGY, 2014, 53 (08) : 1369 - 1376

[6] Self-Delivering RNAi Targeting PD-1 Improves Tumor-Specific T Cell Functionality for Adoptive Cell Therapy of Malignant Melanoma [J]. MOLECULAR THERAPY, 2018, 26 (06) : 1482 - 1493

[7] Oxford BioMedica UK Cystic Fibrosis Gene Therapy Consortium, BOEHR ING IMP INN PA

[8] RXi Pharmaceuticals and Karolinska Institute, ENT COLL DEV SD RXRN

[9] Teewinot Technologies Ltd, US Patent, Patent No. [10,052,303, 10052303]

[1] [Anonymous], FDA APPR GAL MIG TRE

[2] [Anonymous], 2018, M HIGHL COMM MED PRO

[3] Boehringer Ingelheim the UK Cystic Fibrosis Gene Therapy Consortium, IMP INN OXF BIOMEDIC

[4] FDA, FDA APPR NEW TREATM

[5] Type I interferon blockade in systemic lupus erythematosus: where do we stand? [J]. RHEUMATOLOGY, 2014, 53 (08) : 1369 - 1376

[6] Self-Delivering RNAi Targeting PD-1 Improves Tumor-Specific T Cell Functionality for Adoptive Cell Therapy of Malignant Melanoma [J]. MOLECULAR THERAPY, 2018, 26 (06) : 1482 - 1493

[7] Oxford BioMedica UK Cystic Fibrosis Gene Therapy Consortium, BOEHR ING IMP INN PA

[8] RXi Pharmaceuticals and Karolinska Institute, ENT COLL DEV SD RXRN

[9] Teewinot Technologies Ltd, US Patent, Patent No. [10,052,303, 10052303]